: Connect Biopharma stock up more than 40% after trial data


Connect Biopharma Holdings Ltd. CNTB, -3.51% stock rose more than 40% in the extended session Friday after the company said that analysis of a trial involving one of its therapies to treat moderate-to-severe atopic dermatitis showed “rapid and sustained improvement” in signs and symptoms of the illness as compared to a placebo. The stock had ended the regular trading day down 3.5%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleMarket Extra: From SVB’s sudden collapse to Credit Suisse’s fallout: 8 charts show turbulence in financial markets
Next articleBiden White House calls on China’s Xi to talk with Ukraine President Zelensky


Please enter your comment!
Please enter your name here